Back to portfolio

Anvesana is leveraging our RNAseq analysis platform to treat rare genetic disorders caused by gene dosage effects.


Eric Ekland
President and Chief Executive Officer at Anvesana, Inc.

Partner in charge

Jaroslav Luptak


Anvesana is developing therapeutics to treat diseases caused by insufficient protein production. Our core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl. Our platform can query mRNA sequence data to identify regions that can be targeted to up-regulate gene expression. Hundreds of rare genetic diseases are caused by insufficient protein production. Many of these have devastating effects on the affected individual and have no approved disease-modifying therapy.